MedTrace Logo

Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study

NCT02363361 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-03-07

No results posted yet for this study

Summary

This is a phase II, single center, open-label, non randomized clinical study to assess the uptake, safety and tolerability of Imatinib in acute Cervical Spinal Cord Injury patients. The aim is to determine if Imatinib reaches sufficient blood levels when given to patients with cervical spinal cord injury, via a gastric feeding tube, and also evaluate the safety and tolerability of this drug treatment.

Conditions

  • Cervical Spinal Cord Injury

Interventions

DRUG

Imatinib

Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day

Sponsors & Collaborators

  • Professor Mikael Svensson, MD PhD

    lead OTHER

Principal Investigators

  • Mikael Svensson, Prof.MD.PhD · Karolinska University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2020-12-31
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02363361 on ClinicalTrials.gov